ELTX vs ENVB

Elicio Therapeutics, Inc. vs Enveric Biosciences, Inc. — Valuation Comparison 2026

ELTX

Pharmaceutical Preparations
Elicio Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$11.44
Last close
Models
7/13
Active
VS

ENVB

Pharmaceutical Preparations
Enveric Biosciences, Inc.
Quality
3.8
out of 10
Value Trap
39
LOW
Price
$2.30
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ELTX Fair ValueELTX Upside ENVB Fair ValueENVB Upside
Bayesian DCF Intrinsic $2.78 -75.7% $1.91 -17.1%
Earnings Power Value Intrinsic $2.37 -40.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.32 -97.2% $2.36 +2.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELTX vs ENVB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELTX vs ENVB — Which Stock Is More Undervalued?

ELTX scores higher with a 4.1/10 quality rating vs ENVB's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Elicio Therapeutics, Inc. (ELTX) and Enveric Biosciences, Inc. (ENVB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELTX currently trades at $11.44 with a QOC of 4.1/10, while ENVB trades at $2.30 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).